EDGE Experience Diligence Guidance Execution

News

Top Life Science Executives join Edge to launch BIOReal Estate

Melvin D. Booth, former President and Chief Operating Officer of both MedImmune and Human Genome Sciences and Robert J. Walden former Executive Director and Chief Financial Officer of GenVec and Large Scale Biology, have joined EDGE to launch BIOReal Estate. This division of Edge Commercial will be managed by Melvin D. Booth as Chairman and Robert J. Walden as Managing Partner. Together they bring to EDGE over 60 years of executive level life science experience. This unprecedented combination of executive-level life science experience joined with the real estate expertise of EDGE will serve to dramatically differentiate
BIOReal Estate from other advisors.

“I am passionate about the life sciences industry and its mission critical relationship to real estate. Life Science companies require the highest level of expertise due to the unique and strategic nature of their real estate requirements. Bob and I have been on the front lines of the decision making process on numerous occasions for major life science companies. Combined with the expertise of our real estate professionals at EDGE, we offer a unique and valuable ability to address our client’s real estate needs and communicate on a President to President or CFO to CFO level”

– Melvin D. Booth, Chairman – BIOReal Estate

Melvin D. Booth

Mel Booth has more than 35 years of life science experience and during that time has established unparalleled relationships within the industry on local, national and international levels. During his career, Mel was actively involved in expanding two of the most prominent life science companies in the Washington Metropolitan Area, MedImmune and Human Genome Sciences, serving as President and Chief Operating Officer of both companies. In addition to his activities with EDGE, Mel sits on a number of prominent life science company boards including Millipore Corporation, PRA International, Prestwick Pharmaceuticals and Ventria BioScience. Mel is also on Genstar Capital’s Strategic Advisory Board focusing on Life Sciences.

Robert J. Walden

Bob Walden has more than 25 years of CFO/COO level experience with rapidly growing public and private life science companies based in Maryland. In addition to Bob’s in-depth financial and operating knowledge of life science companies, Bob’s real estate experience includes acquisitions and sales, leasing, lab/office build-out, corporate relocation and economic development assistance, and success in helping secure one of the largest corporate relocation incentive packages for a life science company in the Washington Metropolitan Area. Bob’s previous positions include Executive Director of Finance of GenVec, Chief Financial Officer and Division President of Large Scale Biology Corporation, Chief Financial Officer of Osiris Therapeutics and Chief Financial Officer of the American Type Culture Collection.

Posted in General